Quality control of no-carrier-added (YCl3)-Y-90 by estimating the labeling efficiency using its reaction with DOTATOC

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389005%3A_____%2F08%3A00314519" target="_blank" >RIV/61389005:_____/08:00314519 - isvavai.cz</a>
Alternative codes found
RIV/61389005:_____/08:00358999
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Quality control of no-carrier-added (YCl3)-Y-90 by estimating the labeling efficiency using its reaction with DOTATOC
Original language description
The (YCl3)-Y-90 radionuclide precursor (solution of Y-90(3+) in diluted HCl) of high purity and high specific activity is already commercially produced and successfully used in nuclear medicine. At the Nuclear Physics Institute ASCR, the (YCl3)-Y-90 radionuclide precursor is prepared using extraction (SrY)-Sr-90-Y-90 generator (technology of centrifuge extractors with di-2-ethylhexylphosphoric acid, D2EHPA).(1) Its radionuclidic, radiochemical, and chemical purity were examined and specified. The procedure developed for labeling of DOTA-Tyr(3)-octreotide (DOTATOC) with carrier-free Y-86/90 by ROSCH2 at the Institute of Nuclear Chemistry of the University Mainz was optimized and modified in our Department of Radiopharmaceuticals at NPI ASCR as standardlabeling test (SLT) for analytical purposes. The SLT as a method for (YCl3)-Y-90 radionuclide precursor quality control determining its labeling efficiency using ITLC SG chromatography is described and proposed thereinafter.
Czech name
Kontrola kvality nenosičově přidaného (YCl3)-Y-90 určením efektivity značení pomocí jeho reakce s DOTATOC
Czech description
Testovány analýzy radiofarmak pomocí radionuklidového prekurzoru (YCl3)-Y-90. Dosažena efektivita značení větší než 95%.

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Project
<a href="/en/project/FT-TA2%2F081" target="_blank" >FT-TA2/081: *Targeted supercancerostatics of new generation for leucemia therapy.</a><br>
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2008
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)